Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2019-06-28
DOI
10.1080/21645515.2019.1627159
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine
- (2019) Terry Nolan et al. VACCINE
- Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data
- (2019) Philip S. Watson et al. Expert Review of Vaccines
- Antibody persistence and booster responses 24–36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial
- (2018) Federico Martinón-Torres et al. JOURNAL OF INFECTION
- Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines
- (2018) Leszek Szenborn et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes
- (2018) M. Giuliani et al. Scientific Reports
- Emerging experience with meningococcal serogroup B protein vaccines
- (2017) Daniela Toneatto et al. Expert Review of Vaccines
- A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine
- (2017) Robert C. Read et al. VACCINE
- Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial
- (2017) Mildred A. Iro et al. VACCINE
- Meningococcal Antigen Typing System (MATS)-Based Neisseria meningitidis Serogroup B Coverage Prediction for the MenB-4C Vaccine in the United States
- (2017) Gowrisankar Rajam et al. mSphere
- Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults
- (2017) Terry Nolan et al. Open Forum Infectious Diseases
- Can we control all-cause meningococcal disease in Europe?
- (2016) M. Sadarangani et al. CLINICAL MICROBIOLOGY AND INFECTION
- Routinely vaccinating adolescents against meningococcus: targeting transmission & disease
- (2016) Volker Vetter et al. Expert Review of Vaccines
- The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection
- (2016) Ray Borrow et al. Expert Review of Vaccines
- Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements
- (2016) Federico Martinón-Torres JOURNAL OF ADOLESCENT HEALTH
- Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study
- (2016) Sydel R Parikh et al. LANCET
- Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age
- (2016) Matthew D. Snape et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Notes from the Field:Outbreak of Serogroup B Meningococcal Disease at a University — California, 2016
- (2016) Hope H. Biswas et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months
- (2015) Fiona McQuaid et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak
- (2015) L. A. McNamara et al. PEDIATRICS
- Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study
- (2015) Kirsten P. Perrett et al. VACCINE
- Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children
- (2015) Timo Vesikari et al. VACCINE
- Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
- (2014) Robert C Read et al. LANCET
- Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age
- (2014) Fiona McQuaid et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
- (2013) M. D. Snape et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
- (2013) Timo Vesikari et al. LANCET
- Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment
- (2013) Ulrich Vogel et al. LANCET INFECTIOUS DISEASES
- Role of Factor H Binding Protein in Neisseria meningitidis Virulence and Its Potential as a Vaccine Candidate To Broadly Protect against Meningococcal Disease
- (2013) L. K. McNeil et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses
- (2013) Matthew D. Snape et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage
- (2013) Giacomo Frosi et al. VACCINE
- Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
- (2013) Maria Elena Santolaya et al. Human Vaccines & Immunotherapeutics
- The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens
- (2012) Davide Serruto et al. VACCINE
- The changing epidemiology of meningococcal disease in North America 1945–2010
- (2012) Carmen Baccarini et al. Human Vaccines & Immunotherapeutics
- Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children
- (2011) Rosanna Lagos et al. Human vaccines & immunotherapeutics
- Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen
- (2011) David M. Vu et al. VACCINE
- Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans
- (2010) Davide Serruto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus
- (2010) Marzia M. Giuliani et al. VACCINE
- Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
- (2010) Han-Qing Jiang et al. VACCINE
- Global epidemiology of meningococcal disease
- (2009) Lee H. Harrison et al. VACCINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now